The Effect of Gender-affirmative Measures on Breast Perception in Trans Men
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age16+
SponsorMedical University Innsbruck
About this trial
Breast dysphoria in transmasculine or genderdiverse individuals is a distinct psychological burden associated with depression, anxiety and suicidality. The aim is to systematically investigate the effect of GAHT (gender-affirming hormone therapy) and mastectomy on this form of dysphoria.
The primary objective of this study is to analyse and investigate the psychological and physical effects of breast development on trans men or genderdiverse individuals.
A secondary objective is to determine the extent to which the stress affects the well-being of trans men depending on the coping strategies used (binding vs. taping).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
AFAB (Assigned Female At Birth)
before starting GAHT
before mastectomy
Disqualifiers
Ongoing GAHT
Mastectomy already performed
Lack of capacity to give consent
Insufficient knowledge of German
Trial population
Referral to the medical University of Innsbruck Hospital or a cooperating center
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
quality of life questionnaire- iTransQoL, chest dysphoria measure
Other interventionBefore starting treatment, participants should complete the Chest Dysphoria Measure and iTransQoL questionnaires (=time point 0). The second time point for completing the questionnaires again is 3 months after starting hormone therapy. Subsequently, the questionnaires should be completed a third time after breast-affirming surgery. The final survey takes place two years after time point 0, or 6 months after the previous survey.
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Chest Dysphoria Measure Score
Chest Dysphoria Measure Score before GAHT, during GAHT, and after mastectomy. Possible chest dysphoria scores range from 0 to 51, with higher scores indicating greater distress.
Time frame
From enrollment to the end of observation after 2 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov